This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michel, R. B. Articles by Mattes, M. J. Search for Related Content PubMed PubMed Citation Articles by Michel, R. B. Articles by Mattes, M. J.

Center for Molecular Medicine and Immunology, Belleville, New Jersey

Requests for reprints: M. Jules Mattes, Garden State Cancer Center, Center for Molecular Medicine and Immunology, 520 Belleville Avenue, Belleville, NJ 07109. Phone: 973-844-7013; Fax: 973-844-7020. E-mail: mjmattes{at}gscancer.org

Antibodies conjugated to radionuclides emitting low-energy electrons, which include Auger electrons and some conversion electrons, were recently shown to efficiently kill cells bearing a high density of the antigen recognized. The primary purpose of this study was to determine if such killing could be obtained with anti–HER-2 antibodies conjugated to ¹¹¹In, using the chelator benzyl-diethylenetriaminepentaacetic acid, or ¹²⁵I. Target cells were the breast carcinoma SK-BR-3 and the ovarian carcinoma SK-OV-3.ip1. In preliminary experiments, antibody accumulation and catabolism during a 2- to 3-day incubation with antibody was investigated. The level of antibody uptake, in terms of molecules per cell, was high enough such that killing seemed feasible. With an ¹²⁵I label, but not an ¹¹¹In label, increasing the antibody concentration past a certain point caused a decrease in total antibody accumulation, which might be attributed to effects of antibody binding. To test for cytotoxicity, cells were incubated for 2 days with the labeled antibody, then assayed for colony-forming units with a limiting dilution assay. SK-BR-3 cells were strongly killed (3 logs) by antibody 21.1, and 100% kill was obtained by combining two noncompeting antibodies to HER-2 (21.1 and 4D5). SK-OV-3.ip.1 cells were more resistant to killing, but use of the two-antibody mixture produced a surviving fraction of 0.002. ¹¹¹In-labeled antibodies to other high-density antigens, epithelial glycoprotein-1 and epithelial glycoprotein-2, also killed these target cells. In contrast, unlabeled antibodies or a nonreactive-labeled antibody produced much less cytotoxicity. The same experiment with an ¹³¹I label (a ß-particle emitter) resulted in much greater levels of nonspecific cytotoxicity and essentially no specific cytotoxicity. This approach may be effective for therapy of micrometastases.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

² http://ubik.microbiol.washington.edu/computing/quality/jquality.htm

Received 12/17/04; revised 3/31/05; accepted 4/12/05.

This article has been cited by other articles:

				J. H. Weisburg Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics J. Nucl. Med., September 1, 2008; 49(9): 1405 - 1407. [Full Text] [PDF]

				D. L. Costantini, C. Chan, Z. Cai, K. A. Vallis, and R. M. Reilly 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer J. Nucl. Med., August 1, 2007; 48(8): 1357 - 1368. [Abstract] [Full Text] [PDF]

				A. Wicki, D. Wild, D. Storch, C. Seemayer, M. Gotthardt, M. Behe, S. Kneifel, M. J. Mihatsch, J.-C. Reubi, H. R. Macke, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma Clin. Cancer Res., June 15, 2007; 13(12): 3696 - 3705. [Abstract] [Full Text] [PDF]